2145 Masitinib plus FOLFIRI for second-line treatment of metastatic colorectal cancer: 2-year follow-up of phase open label trial. (September 2015) - Taieb, J.; Borg, C.; Lecomte, T.; Lepere, C.; Chatellier, T.; Smith, D.; Dubreuil, P; Mansfield, C.; Moussy, A.; Hermine, O.